{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 42,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "The chart shows a stacked bar chart of revenue over time, split by China and EM excluding China.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/18",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.51,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Revenue anticipated to continue growing ahead of the long-term ambition of mid to high single-digit growth",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b8bbd2-5f81-4e50-8f96-876ba3209643",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "chart",
      "text": "Revenue growth in emerging markets from Q1 2018 to Q2 2021",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ba4483a-1b3a-4241-aa77-e74973ea2fd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.51,
        "y": 0.3
      },
      "kind": "list",
      "text": "Oncology +6%: Tagrisso (+10%); March 2021 NRDL inclusion\nNew CVRM +28%: Forxiga (+77%); roxadustat ($92m)\nRespiratory & Immunology +10%: Pulmicort ($405m, +2%); Symbicort ($306m, +2%)\nDiversified growth: AP +4%, MEA +73%, LA +48%, Russia +6%; benefit from vaccine shipments\n2021 China patient access: major NRDL inclusion Tagrisso 1L but VBP impact to now Pulmicort, Brilinta, Nexium and legacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d0ae51a-8140-40c1-a8ae-4739f50b676b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.55,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Performance driven by new medicines up 29% (35% of total revenue; $1.8bn)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e875a52e-b00a-49d1-98ac-c96d97b61bbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.51,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 1. Total revenue at CER 2. Asia Pacific 3. Middle East, Africa and other 4. Latin America.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e4779f7-3252-4c67-a7a1-a62a7b0f37e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Emerging markets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b379ab6-5e08-48c0-b878-d3184adcbff4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Diverse and solid growth",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01535888-f653-4d5c-8955-3820a5a0591f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Pyramid Principle",
      "slug": "pyramid-principle",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "7e24467b-adb8-46ae-895e-c859929baa0b",
      "evidence": "paragraph/paragraph: Performance driven by new medicines up 29% (35% of total revenue; $1.8bn)",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "4d44e7fe-d7a8-49cd-a7ca-8ebf40e8c11e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides detailed KPI overviews and key messages",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}